Degarelix Acetate (Firmagon®)

Common name: Degarelix Acetate
Brand name: Firmagon®
 

What is Degarelix Acetate?

Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced (metastatic) prostate cancer by blocking the release of testosterone.
 

How is Degarelix Acetate administered?

Degarelix Acetate is administered by subcutaneous injection in the abdominal area.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received degarelix acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Breast enlargement
  • Constipation
  • Difficulties sleeping
  • Fatigue
  • Frequent urination
  • Headaches
  • Hot flashes
  • Nausea
  • Pain / redness at site of injection
  • Reduced sex drive (low libido)


Is Degarelix Acetate covered in my province or territory?

Degarelix acetate is covered by provincial drug programs in:
  • British Columbia
  • Manitoba
  • New Brunswick
  • Northwest Territories
  • Nova Scotia
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
​Degarelix acetate is not covered by provincial drug programs in:
  • ​Alberta
  • Newfoundland & Labrador
  • Yukon

Unknown if degarelix acetate is covered by provincial drug programs in:
  • Nunavut

Firmagon Care Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Go to http://www.ferring.ca/en/patient-assistance-programs/ for more information and to see if you qualify for this program. Patients can call 1-866-210-0399 for access to a free nurse injection clinic.
 

 

Last Reviewed: July 2017

Prostate Cancer Awareness Month

Donate Now!


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada launches first national program in radionuclide therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More

Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More


Click here for news archive